Jul. 9 at 4:14 PM
It appears
$VRNA is being acquired for 0.45X cumulative 10-year analyst consensus revenue estimates. This is on the high end versus peer commercial-stage bio M&A as listed below (most are acquired for 0.32 to 0.41X 10 year revenues). VRNA will file a 14D9 in about 4 weeks that will include the revenue forecast prepared by VRNA & provided Merck that may materially differ from analysts.
Merck is buying VRNA roughly 12.5 months from FDA approval
This transaction should be a good thing for bios like
$TARS &
$SNDX with recent approvals that trade for well less than 0.20X 10-year revenue forecasts.
Others trading at low multiple of projected revenues include
$FOLD &
$APLS.
This is not investment advice.
